Skip to content

Complications of Ethanol-amine Oleate Intralesional Sclerotherapy

Complications of Ethanol-amine Oleate Intralesional Sclerotherapy Injections of Maxillofacial Venous Malformations in Pediatric Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04930952
Enrollment
15
Registered
2021-06-18
Start date
2019-02-28
Completion date
2021-03-03
Last updated
2026-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous Malformation

Keywords

Maxillofacial, Pediatric, Venous Malformations, Ethanol-amine Oleate

Brief summary

The aim of this study is to clarify complications of Ethanolamine Oleate intralesional injections of maxillofacial venous formations in pediatric patients

Detailed description

Maxillofacial Venous malformations cause many functional and esthetic complications in children, intralesional sclerotherapy is the best choice of treatment; and Ethanol-amine Oleate has been the most commonly used sclerosing agent. The aim of this study is to clarify complications of Ethanolamine Oleate intralesional injections of maxillofacial venous formations

Interventions

DRUGEthanol-amine Oleate Sclerotherapy Injection

Intralesional Sclerotherapy Injection

Sponsors

Suez Canal University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
No minimum to 12 Years
Healthy volunteers
Yes

Inclusion criteria

maxillofacial venous malformation \-

Exclusion criteria

1. Patients with lung, liver, or kidney diseases 2. Patients with Klippel-Trenaunay syndrome 3. Patients mental or physical disabilities

Design outcomes

Primary

MeasureTime frameDescription
Clinical Response12 monthsComplete Response - Marked Improvement - Moderate Improvement - No Response

Countries

Egypt

Contacts

PRINCIPAL_INVESTIGATORSarah Arafat, MSc

Assistant Lecturer

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 14, 2026